
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    1. Key functional markers and pathways<br><br>I‚Äôll first group the most informative genes by functional category and briefly note their roles:<br><br>**a. Cytotoxic / effector program**<br>- **FGFBP2** ‚Äì hallmark of highly cytotoxic NK and CD8 T cells (especially terminally differentiated effector cells); strongly enriched in NK / cytotoxic T populations.<br>- **GNLY (granulysin)** ‚Äì cytotoxic granule protein; expressed in NK cells and cytotoxic CD8 T cells.<br>- **GZMM** ‚Äì granzyme M; cytotoxic effector protease, enriched in NK cells and some cytotoxic T cells.<br>- **XCL2** ‚Äì chemokine produced by activated cytotoxic T and NK cells; often co-expressed with XCL1 in cytotoxic lymphocytes.<br>- **TBX21 (T-bet)** ‚Äì Th1 / type 1 cytotoxic transcription factor; drives IFN-Œ≥‚Äìproducing cytotoxic programs in NK and CD8 T cells.<br>- **STAT4** ‚Äì key transcription factor in IL-12/IFN-Œ≥ axis; supports Th1 / type 1 cytotoxic differentiation.<br>- **PYHIN1** ‚Äì interferon-inducible innate immune gene; often up in activated cytotoxic lymphocytes.<br><br>These collectively indicate a **type 1, cytotoxic, IFN-Œ≥‚Äìoriented lymphocyte** program.<br><br>**b. NK / innate-like lymphocyte receptors**<br>- **KLRB1 (CD161)** ‚Äì C-type lectin receptor; expressed on NK cells, MAIT cells, some Œ≥Œ¥ T cells, and subsets of memory CD4/CD8 T cells. In brain, often marks tissue-resident/innate-like T cells.<br>- **KLRC1 (NKG2A)** ‚Äì inhibitory NK receptor; expressed on NK cells and some CD8 T cells with NK-like features.<br>- **KLRF1 (NKp80)** ‚Äì activating NK receptor; enriched in NK cells and highly cytotoxic CD8 T cells.<br>- **KLRD1 (CD94)** ‚Äì NK receptor forming heterodimers with NKG2 family (e.g., KLRC1); canonical NK / NK-like CD8 T marker.<br><br>This KLR cluster is characteristic of **NK cells and NK-like cytotoxic T cells**.<br><br>**c. TCR signaling and T cell identity**<br>- **TRBC2, TRGC2** ‚Äì TCR Œ≤ and Œ≥ constant regions; confirm **T cell lineage** (Œ±Œ≤ and/or Œ≥Œ¥ T cells).<br>- **CD3E, CD247 (CD3Œ∂)** ‚Äì core TCR-CD3 complex components; pan-T cell markers.<br>- **CD2, CD5, CD28, CD48, ICOS, CD52** ‚Äì canonical T cell surface molecules; ICOS more associated with activated/memory T cells.<br>- **ZAP70, ITK, LCK-family‚Äìrelated (MATK)** ‚Äì proximal TCR signaling kinases; T cell activation machinery.<br>- **SKAP1, LAX1, SH2D1A (SAP), HSH2D** ‚Äì adaptors in TCR and co-receptor signaling; SH2D1A is SAP, important in SLAM-family signaling in T/NK cells.<br>- **SLAMF1 (CD150), CD96** ‚Äì SLAM family and related receptors; modulate T/NK activation and adhesion.<br>- **CD69** ‚Äì early activation marker; also associated with tissue residency (TRM) in T cells, especially in non-lymphoid tissues like brain.<br>- **TNFRSF18 (GITR)** ‚Äì costimulatory TNFR family member; upregulated upon T cell activation.<br>- **CD52** ‚Äì pan-lymphocyte marker (T, B, NK), but here in a TCR+ context.<br><br>These firmly establish the cluster as **T-lineage lymphocytes with strong activation signaling**.<br><br>**d. Chemokine receptors / trafficking / tissue residency**<br>- **CCR7** ‚Äì central memory / na√Øve T cell homing receptor (LN-tropic); usually downregulated in terminal effector cells but can persist in some memory subsets.<br>- **CXCR4** ‚Äì chemokine receptor for CXCL12; involved in homing to bone marrow and also CNS trafficking; often expressed in T cells.<br>- **S1PR4** ‚Äì sphingosine-1-phosphate receptor; involved in lymphocyte trafficking and egress.<br>- **P2RY10** ‚Äì purinergic receptor; expressed in T cells, involved in chemotaxis and migration.<br>- **CD69** (again) ‚Äì antagonizes S1PR1 and supports tissue retention; in brain, strongly associated with **tissue-resident T cells (TRM)**.<br><br>Pattern suggests **tissue-resident / tissue-retained, activated T cells** with some memory-like features.<br><br>**e. Cytokine / survival / differentiation receptors**<br>- **IL7R (CD127)** ‚Äì hallmark of na√Øve and memory T cells (especially CD4, but also memory CD8); low in terminal effector CD8 T and NK cells. Its presence suggests **non-terminal, memory-like T cells**.<br>- **IL2RB (CD122)** ‚Äì IL-2/IL-15 receptor Œ≤ chain; high in NK cells and activated/memory CD8 T cells.<br>- **LTB** ‚Äì lymphotoxin Œ≤; TNF superfamily member, expressed in activated T cells, involved in lymphoid tissue organization.<br><br>**f. Transcriptional regulators / signaling**<br>- **TXK** ‚Äì Tec family kinase enriched in Th1 / cytotoxic T cells; supports IFN-Œ≥ production.<br>- **CAMK4** ‚Äì CaMKIV; involved in T cell activation and transcriptional responses (e.g., CREB).<br>- **STAT4, TBX21** ‚Äì as above, Th1/cytotoxic axis.<br>- **ZNF831** ‚Äì transcription factor enriched in memory/activated T cells, including tissue-resident subsets.<br><br>**g. Other immune / lymphocyte-associated genes**<br>- **FCMR (TOSO)** ‚Äì Fc receptor for IgM; expressed in B cells and some T cell subsets (especially regulatory/activated T cells).<br>- **RNF125** ‚Äì E3 ubiquitin ligase; interferon-inducible, enriched in activated T/NK cells.<br>- **SYTL3, IPCEF1, TC2N, SPOCK2** ‚Äì less canonical but seen in activated/migratory lymphocytes; SPOCK2 often in T cells and some CNS contexts.<br>- **P2RY10, S1PR4** ‚Äì as above, migration/chemotaxis.<br><br>Overall, the functional profile is **activated, cytotoxic, type 1‚Äìpolarized T cells with NK-like features and tissue-resident characteristics**.<br><br>---<br><br>2. Key cell type markers (tissue/cell identity)<br><br>From the above, the most informative **cell-type‚Äìdefining markers**:<br><br>**T cell lineage**<br>- **TRBC2, TRGC2, CD3E, CD247, CD2, CD5, CD28, ZAP70, ITK, SKAP1, LAX1, SH2D1A, SLAMF1, ICOS, CD52**  <br>‚Üí unequivocal **T lymphocyte** identity.<br><br>**Cytotoxic / NK-like T**<br>- **FGFBP2, GNLY, GZMM, XCL2, TBX21, STAT4, IL2RB, KLRD1, KLRC1, KLRF1, KLRB1, CD96, PYHIN1**  <br>‚Üí **cytotoxic effector T cells with NK receptor expression** (NK-like CD8 T or innate-like T).<br><br>**Memory / tissue-resident / activated**<br>- **IL7R, CCR7, CXCR4, CD69, ICOS, LTB, ZNF831, S1PR4, P2RY10**  <br>‚Üí **activated memory / tissue-resident T cells**, likely in a non-lymphoid tissue (brain).<br><br>**Brain tissue context**<br>- Brain scRNA-seq datasets (e.g., human cortex, glioma microenvironment) consistently show:<br>  - **CD69+ KLRB1+ TBX21+ GNLY+ T cells** as **brain-resident or infiltrating cytotoxic T cells**.<br>  - NK cells in brain typically have **stronger NK receptor signatures but lack IL7R, CCR7, TRGC2** and often show more canonical NK markers (NKG7, PRF1, GZMB, KLRK1, etc.), which are not in the top list here.<br><br>Thus, the markers are most consistent with **T cells rather than ‚Äúpure‚Äù NK cells**, but with a strong NK-like cytotoxic program.<br><br>---<br><br>3. Cross-referencing with scRNA-seq databases and literature<br><br>Cross-checking this signature against known references:<br><br>- **Human brain / CNS immune atlases** (e.g., Sankowski et al. Nature 2019; Schirmer et al. Nat Neurosci 2019; T cell infiltrates in glioma and MS lesions):<br>  - Report **CD3E+ CD2+ CD5+ KLRB1+ GNLY+ GZMM+ TBX21+ CD69+** clusters annotated as **CD8 cytotoxic T cells / tissue-resident T cells**.<br>  - FGFBP2+ GNLY+ GZMM+ XCL1/2+ clusters are typically annotated as **cytotoxic CD8 T / NK-like T** rather than classical NK in CNS.<br><br>- **Immune reference atlases** (e.g., Azimuth PBMC, Human Cell Atlas immune reference):<br>  - **FGFBP2+ GNLY+ GZMM+ KLRD1+ KLRC1+ KLRF1+ TBX21+ STAT4+ IL2RB+** clusters map to **CD8 effector / NK-like T** and **NK cells**.<br>  - **IL7R+ CCR7+ KLRB1+** is more typical of **memory T cells (often CD4)**, but when combined with **FGFBP2/GNLY/GZMM/TBX21**, it points to **memory/effector CD8 T** with some retained homing receptors.<br><br>- **MAIT / Œ≥Œ¥ T references**:<br>  - MAIT cells: KLRB1+, TRAV1-2+, SLC4A10, IL18RAP, RORC, etc. Those MAIT-specific markers are not present.<br>  - Œ≥Œ¥ T cells: TRGC2+ is present, but we lack strong Œ≥Œ¥-specific V gene signatures; in bulk marker lists, Œ≥Œ¥ T cells often show **TRGC2, TRDC, KLRD1, KLRB1**, but also distinct cytokine patterns (IL17A/F for Œ≥Œ¥17, etc.), which are not evident here. TRGC2 alone is not sufficient to call Œ≥Œ¥ T as the dominant identity in a mixed TCR repertoire.<br><br>Given the combination of **strong TCR signaling, cytotoxic effector genes, NK receptors, and IL7R/CCR7/CD69**, the best match in reference atlases is **CD8+ cytotoxic / NK-like tissue-resident T cells** in brain.<br><br>---<br><br>4. Most probable general cell type<br><br>General class: **T lymphocyte (T cell)**<br><br>Not a microglial, astrocytic, neuronal, oligodendroglial, or endothelial signature. The presence of **TCR components (TRBC2/TRGC2, CD3E, CD247)** and multiple T-lineage markers rules out non-lymphoid brain cells.<br><br>Within lymphocytes, the strong TCR signature and IL7R/CCR7 argue against ‚Äúpure‚Äù NK cells and in favor of **T cells with NK-like features**.<br><br>---<br><br>5. Top 3 most probable sub cell types (ranked)<br><br>Within T cells, considering brain tissue context:<br><br>### 1) Brain-infiltrating / tissue-resident **CD8+ cytotoxic NK-like T cells** (most likely)<br><br>Rationale:<br>- **Cytotoxic/NK-like program**: FGFBP2, GNLY, GZMM, XCL2, TBX21, STAT4, IL2RB, KLRD1, KLRC1, KLRF1, CD96.<br>- **T cell identity**: TRBC2, CD3E, CD247, CD2, CD5, CD28, ZAP70, ITK, SLAMF1, SH2D1A.<br>- **Tissue residency / activation**: CD69, CXCR4, S1PR4, P2RY10, ZNF831.<br>- **Memory-like features**: IL7R, CCR7 (though CCR7 can be heterogeneous; some cells may be transitioning from central memory to effector).<br>- In human brain datasets, such clusters are typically annotated as **CD8+ cytotoxic T cells** or **CD8+ TRM / NK-like T cells**.<br><br>Even though CD8A/CD8B are not in the provided list, the combination of **FGFBP2+ GNLY+ GZMM+ TBX21+ KLRD1+ KLRC1+** is much more characteristic of **CD8/NK-like cytotoxic T cells** than CD4 T cells.<br><br>**Most likely final subtype**:  <br>**CD8+ cytotoxic, NK-receptor‚Äìexpressing, tissue-resident/memory T cells (brain-resident cytotoxic T cells).**<br><br>---<br><br>### 2) **Cytotoxic Œ≥Œ¥ T cells / innate-like T cells**<br><br>Rationale:<br>- **TRGC2** suggests presence of Œ≥-chain TCR transcripts.<br>- Œ≥Œ¥ T cells often express **KLRB1, KLRD1, KLRC1, KLRF1, GNLY, GZMM, TBX21**, and can be highly cytotoxic.<br>- In some tissues, Œ≥Œ¥ T cells show **IL7R** and tissue-resident markers (CD69, CXCR4).<br>- However:<br>  - We lack strong Œ≥Œ¥-specific V gene markers (e.g., TRDV1/2/3, TRGVs) in the top list.<br>  - Many of the markers (CCR7, IL7R, ICOS) are more typical of Œ±Œ≤ memory T cells.<br>  - TRGC2 can be expressed at low levels in Œ±Œ≤ T cells or appear due to ambient RNA / mixed repertoire.<br><br>Thus, **Œ≥Œ¥ T cells** are a plausible minority or alternative interpretation, but less likely as the dominant identity of this cluster than **CD8 Œ±Œ≤ cytotoxic T cells**.<br><br>---<br><br>### 3) **Th1-polarized CD4+ memory / tissue-resident T cells with cytotoxic features**<br><br>Rationale:<br>- **IL7R, CCR7, KLRB1, ICOS, LTB, ZNF831** ‚Äì classic for **CD4 memory / Th subsets**.<br>- **TBX21, STAT4** ‚Äì Th1 polarization.<br>- Some CD4 Th1 cells can express **GNLY, GZMM, XCL2** and even low-level NK receptors (KLRB1, KLRD1).<br>- Brain-resident CD4 TRM have been described with **CD69+, CXCR4+, KLRB1+** profiles.<br><br>However:<br>- The **FGFBP2+ GNLY+ GZMM+ KLRD1+ KLRC1+ KLRF1+** combination is much more typical of **CD8/NK-like cytotoxic cells** than of classical Th1 CD4 cells.<br>- CD4 cytotoxic Th1 cells exist but are less common and usually not as strongly FGFBP2-high.<br><br>Thus, a **Th1-like CD4 memory TRM** is a reasonable but less likely alternative.<br><br>---<br><br>6. Concise summary of analysis<br><br>- The marker set is dominated by **TCR components (TRBC2, TRGC2, CD3E, CD247)** and T cell signaling molecules (ZAP70, ITK, SKAP1, LAX1, SH2D1A, SLAMF1), confirming **T cell identity**.<br>- Strong **cytotoxic and NK-like features** (FGFBP2, GNLY, GZMM, XCL2, TBX21, STAT4, IL2RB, KLRD1, KLRC1, KLRF1, CD96) indicate **cytotoxic effector T cells with NK receptor expression**.<br>- **IL7R, CCR7, KLRB1, ICOS, CD69, CXCR4, S1PR4, P2RY10, ZNF831** support an **activated, memory / tissue-resident phenotype**, consistent with T cells residing in or infiltrating brain tissue.<br>- Cross-referencing with human brain and immune scRNA-seq atlases, the best match is **CD8+ cytotoxic, NK-like, tissue-resident/memory T cells**.<br><br>**Final annotation:**<br>- **General cell type:** T lymphocyte  <br>- **Most likely subtype:** **CD8+ cytotoxic NK-receptor‚Äìexpressing tissue-resident/memory T cells (brain-resident cytotoxic T cells)**  <br>- **Secondary possibilities:** (2) cytotoxic Œ≥Œ¥ T cells; (3) Th1-polarized CD4 memory/tissue-resident T cells with cytotoxic features.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">T lymphocyte (T cell)</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>CD8+ cytotoxic NK-receptor‚Äìexpressing tissue-resident/memory T cells (brain-resident cytotoxic T cells)</li><li>Cytotoxic Œ≥Œ¥ T cells / innate-like T cells</li><li>Th1-polarized CD4+ memory / tissue-resident T cells with cytotoxic features</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li>CD8+ cytotoxic NK-like T cells</li><li>Cytotoxic Œ≥Œ¥ T cells</li><li>Th1-like CD4+ memory/tissue-resident T cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">nan</div>
                        <div class="scoring-content">
                            Error: Error code: 400 - {'error': {'message': "Unsupported parameter: 'max_tokens' is not supported with this model. Use 'max_completion_tokens' instead.", 'type': 'invalid_request_error', 'param': 'max_tokens', 'code': 'unsupported_parameter'}}<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    